The authors reported that the treatment produced substantial, sustained, clinically relevant mean weight loss of 14.9% , with 86% of treated participants attaining at least 5% weight loss [1]
Adjusted EBITDA was $44.3 million for Q1 compared to $91.1 million for the first quarter of 2025
Acute needs (recovery, immune support): Weekly for 3-4 weeks, then taper
Frequently Asked Questions How many days until I notice semaglutide lowering my blood sugar
Labeling pens with discard dates Tracking usage dates becomes even more crucial during travel disruptions
[ Observational study, general recommendation ] Key question In individuals with diabetes who are being discharged from the hospital, does reviewing the treatment plan and adjusting the current therapeutic regimen as needed, compared to discharge without such review or adjustment, improve post-discharge glycemic control